Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.
Specifically, we aim to measure differences in drug liking with a VAS (0 - 100) questionnaire. Additionally, we will monitor neural activity recording a frontal electroencephalogram (EEG) to detect changes in brain signals associated with opioid drug effects. By comparing behavioral and neurophysiological data across treatment and control groups, this study seeks to explore the therapeutic potential of this medication.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Drug | Experimental | Participants receive study drug prior to fentanyl administration before their procedure. |
|
| Placebo | Placebo Comparator | Participants receive placebo prior to fentanyl administration before their procedure. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amisulpride | Drug | Medication administered as a single intravenous dose. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Drug Liking Rating | Change in drug liking rating (0-100), anchored by divert "not at all=0" and "as much as possible=100". | One minute before and 1, 3, and 5 minutes after fentanyl administration |
| Measure | Description | Time Frame |
|---|---|---|
| EEG band power | Assessment of the change in power of the frontal EEG canonical frequency bands measured in decibles (dB). | From administration of the study drug to about 1 hour after. |
| Change in Sedation Rating |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Patrick L Purdon, PhD | Contact | 6507367331 | ppurdon@stanford.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford Hospital | Palo Alto | California | 94304 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000077582 | Amisulpride |
| ID | Term |
|---|---|
| D001549 | Benzamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D001565 | Benzoates |
| D000146 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Matching Placebo given by single intravenous (IV) administration. |
|
Change in self-reported sedation rating (0-100), anchored by divert "not at all=0" and "as much as possible=100".
| One minute before and 1, 3, and 5 minutes after fentanyl administration |
| Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |